Abstract
Objectives
Design
Setting and Participants
Measures
Results
Conclusions and Implications
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the American Medical Directors AssociationReferences
- Global, regional, and national burden of Parkinson's disease, 1990–2016: A systematic analysis for the global burden of disease study 2016.Lancet Neurol. 2018; 17: 939-953
- The Sydney Multicenter Study of Parkinson's disease: The inevitability of dementia at 20 years.Mov Disord. 2008; 23: 837-844
- Direct economic impact of Parkinson's disease: A research survey in the United Kingdom.Mov Disord. 2003; 18: 1139-1145
- Nursing home and end-of-life care in Parkinson disease.Neurology. 2015; 85: 413-419
- Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study.J Am Geriatr Soc. 2000; 48: 938-942
- Risk factors for nursing home placement in advanced Parkinson's disease.Neurology. 2012; 43: 2227
- Care requirements of a prevalent population of people with idiopathic Parkinson's disease.Age Ageing. 2009; 39: 57-61
- Study protocol: Care of late-stage Parkinsonism (CLaSP).BMC Neurol. 2018; 18: 185
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation.J Chronic Dis. 1987; 40: 373-383
- Parkinson's measurement levodopa equivalent dose calculator.(Available at:)https://www.parkinsonsmeasurement.org/toolBox/levodopaEquivalentDose.htmDate accessed: July 12, 2019
- Movement disorder Society-Sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): Scale presentation and clinimetric testing results.Mov Disord. 2008; 23: 2129-2170
- The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.Mov Disord. 2007; 22: 1901-1911
- The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia.Neurology. 1994; 44: 2308-2314
- Palliative care for advanced Parkinson disease: An interdisciplinary clinic and new scale, the ESAS-PD.Park Relat Disord. 2012; 18: S6-S9
- Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder Society task force.Mov Disord. 2007; 22: 2314-2324
- mice: Multivariate imputation by chained equations in R.J Stat Software. 2011; 45 (Available at:): 1-67https://www.jstatsoft.org/v45/i03/Date accessed: June 14, 2019
- R: A language and environment for statistical computing.R Foundation for Statistical Computing, Vienna, Austria2019 (Available at:)https://www.R-project.org/Date accessed: June 14, 2019
- Relationship status and long-term care facility use in later life.J Gerontol Ser B Psychol Sci Soc Sci. 2016; 71: 711-723
- Social determinants of duration of last nursing home stay at the end of life in Switzerland: A retrospective cohort study Health services research.BMC Geriatr. 2015; 15: 1-8
- Factors influencing home discharge after inpatient rehabilitation of older patients: A systematic review.BMC Geriatr. 2016; 16: 5
- Global estimates of informal care. 2018:Alzheimer's disease international.(Available at:)https://www.alz.co.uk/adi/pdf/global-estimates-of-informal-care.pdfDate accessed: June 14, 2019
- Dementia associated with Parkinson's disease: Applying the movement disorder Society task force criteria.Park Relat Disord. 2011; 17: 621-624
- Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review.Mov Disord. 2019; 34: 180-198
- Treating dopamimetic psychosis in Parkinson's disease: Structured review and meta-analysis.Eur Neuropsychopharmacol. 2007; 17: 165-171
- Diagnosis and pharmacological management of Parkinson's disease: Summary of SIGN guidelines.BMJ. 2010; 340: 206
- Worldwide differences in regulations of clozapine use.CNS Drugs. 2016; 30: 149-161
- Pimavanserin: A novel therapeutic option for Parkinson disease psychosis.Neurol Clin Pract. 2017; 7: 282.1-282.12
- Impulse control and related disorders in Parkinson's Disease. 76. Elsevier Inc, 2018 1st ed.
Article info
Publication history
Footnotes
The CLaSP study is funded by the European Commission (Joint Program–Neurodegenerative Disease Research “European research projects for the evaluation of healthcare policies, strategies, and interventions for Neurodegenerative Diseases”) through national funding bodies in all 6 countries (Economic and Social Research Council ES/L009250/1; BMBF, Marburg, Germany 01ED1403A, Munich, Germany 01ED1403B, Bordeaux, France: ANR-13-JPHC-0001-07, Lisbon, Portugal: HC/0002/2012, Lund, Sweden; HC-559-002, Nijmegen, Holland, 733051003). A. Schrag was supported by the National Institute for Health Research UCL/UCLH Biomedical Research Center. A. Hommel was supported by co-funding of Groenhuysen organization and Stichting Beroepsopleiding Huisartsen.